Skip to main content

Table 3 Predictors of increased diffuse interstitial or replacement myocardial fibrosis (highest quartile)

From: Systemic proinflammatory−profibrotic response in aortic stenosis patients with diabetes and its relationship with myocardial remodeling and clinical outcome

Diffuse myocardial fibrosis (ECV)

 

Univariable

Multivariable model 1a

Multivariable model 2b

Crude HR

p-value

Adjusted HR

p-value

Adjusted HR

p-value

Age (years)

1.00 (0.97–1.03)

0.772

0.98 (0.95–1.01)

0.234

  

Male

1.18 (0.66–2.11)

0.578

1.11 (0.61–2.04)

0.730

  

Diabetes

2.17 (1.17–4.04)

0.015

1.94 (0.99–3.79)

0.052

1.90 (1.00–3.61)

0.049

Hypertension

1.48 (0.80–2.71)

0.208

1.29 (0.66–2.51)

0.456

1.88 (0.96–3.68)

0.064

Atrial fibrillation

0.93 (0.38–2.28)

0.874

0.82 (0.32–2.08)

0.675

  

Ischemic heart disease

2.18 (1.14–4.17)

0.018

1.82 (0.90–3.66)

0.094

  

Peak aortic velocity (m/s)

0.76 (0.54–1.09)

0.139

0.83 (0.57–1.19)

0.311

  

Replacement fibrosis (LGE)

 

Univariable

Multivariable model 1a

Multivariable model 2b

Crude HR

p-value

Adjusted HR

p-value

Adjusted HR

p-value

Age (years)

1.03 (0.99–1.06)

0.100

1.01 (0.98–1.05)

0.427

  

Male

2.17 (1.20–3.93)

0.010

2.14 (1.14–4.01)

0.018

2.10 (1.13–3.92)

0.019

Diabetes

3.32 (1.80–6.12)

 < 0.001

2.96 (1.53–5.73)

0.001

3.04 (1.60–5.76)

 < 0.001

Hypertension

1.44 (0.79–2.62)

0.235

1.18 (0.60–2.30)

0.631

  

Atrial fibrillation

1.30 (0.57–3.01)

0.533

1.09 (0.45–2.68)

0.848

  

Ischemic heart disease

2.54 (1.34–4.81)

0.004

1.78 (0.89–3.56)

0.105

1.81 (0.92–3.58)

0.085

Peak aortic velocity (m/s)

1.03 (0.73–1.45)

0.869

1.21 (0.83–1.76)

0.312

  
  1. Important clinical variables are shown in the first column
  2. ECV, extracellular volume fraction; HR, hazard ratio; LGE, late gadolinium enhancement
  3. aModel 1 was adjusted for all variables in the first column
  4. bModel 2 was constructed with stepwise backward selection from variables presented in the first column